Catalyst Capital Advisors
RARX

Catalyst Capital Advisors’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Catalyst Capital Advisors’s Portfolio RARX Stock Details RARX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-480
Closed -$10K – 595
2017
Q1 		$10K Buy
+480
New +$9.18K ﹤0.01% 414

Other funds holding RARX

NEA Management Company
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Novo Holdings A/S
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Rock Springs Capital Management
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Tekla Capital Management
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Catalyst Capital Advisors's RARX Position: Q2 2017 in Review

Catalyst Capital Advisors sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q2 2017, closing a stake of 480 shares — an estimated $10K sold.

Catalyst Capital Advisors first reported a position in RARX in Q1 2017 and held it in 1 quarter. The position peaked at $10K in Q1 2017. 65 funds tracked by Wall St. Rank hold RARX as of Q2 2017.

  • Catalyst Capital Advisors reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q2 2017 after selling out during the quarter.
  • Catalyst Capital Advisors sold 480 Ra Pharmaceuticals, Inc. Common Stock shares in Q2 2017, an estimated $10K.
  • Catalyst Capital Advisors first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q1 2017 and held it in 1 quarter.
  • Catalyst Capital Advisors's Ra Pharmaceuticals, Inc. Common Stock position peaked at $10K in Q1 2017.
  • 65 funds tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q2 2017.

Based on Catalyst Capital Advisors's 13F filing for Q2 2017, filed 2 Aug 2017.